Skip to main content

Table 4 Mean difference in, and 95% confidence interval for, change from baseline hearing level in dB for patients receiving regimens containing ZDV or ddI, estimated by GEE model adjusting for time since beginning therapy, baseline hearing level, and age.*

From: A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people

  Low Frequency PTA† High Frequency PTA
  All patients Age < 35 years Age ≥ 35 years All patients Age < 35 years Age ≥ 35 years
ZDV 4.0 (-1.4 – 9.5) 3.9 (-0.6 – 8.4) 4.5 (-2.1 – 11.0)
p = 0.70
1.2 (-1.2 – 3.5) 1.5 (-1.7 – 4.8) 0.80 (-2.4 – 4.0)
p = 0.75
ddI - 2.6 (-6.1 – 0.9)
p = 0.91
- 0.6 (-2.5 – 1.2) - 5.4 (-13.8 – 3.1)
p = 0.31
0.2 (-3.1 – 2.7) - 0.2 (-3.3 – 2.8) - 0.1 (-3.7 – 3.5)
p = 0.95
Combined
(per 100 drug-days) ‡
- 0.08 (-1.2 – 1.0
) p = 0.89
-0.28 (-0.80 – 1.4)
p = 0.61
-0.45 (-1.6 – 0.69)
p = 0.44
-0.047 (-1.4 – 1.3)
p = 0.75
0.098 (-2.0 – 1.3)
p = 0.92
-0.22 (-1.6 – 1.2)
p = 0.70
  1. *A positive value indicates worsening hearing level; a negative value indicates improved hearing level.
  2. †Pure Tone Average
  3. ‡Cumulative total number of days each patient took ZDV and ddI